We recently found that buformin significantly inhibits cell adhesion and invasion in endometrial cancer cells [63] and NT1014, a novel biguanide and AMPK activator, is able to reduce serum VEGF production and MMP expression in ovarian cancer tissues in a transgenic mouse model of ovarian cancer [50]. This evidence concerns the gene VEGFA and ovarian carcinoma.